Arterial Spin-labeling and MR Spectroscopy in the Differentiation of Gliomas

Overview

Journal AJNR Am J Neuroradiol

Specialty Neurology

Date 2007 Sep 26

PMID 17893221

Citations 47

Authors

S Chawla

S Wang

R L Wolf

J H Woo

J Wang

D M ORourke

K D Judy

M S Grady

E R Melhem

H Poptani

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Noninvasive grading of gliomas remains a challenge despite its important role in the prognosis and management of patients with intracranial neoplasms. In this study, we evaluated the ability of cerebral blood flow (CBF)-guided voxel-by-voxel analysis of multivoxel proton MR spectroscopic imaging ((1)H-MRSI) to differentiate low-grade from high-grade gliomas.

Materials And Methods: A total of 35 patients with primary gliomas (22 high grade and 13 low grade) underwent continuous arterial spin-labeling perfusion-weighted imaging (PWI) and (1)H-MRSI. Different regions of the gliomas were categorized as "hypoperfused," "isoperfused," and "hyperperfused" on the basis of the average CBF obtained from contralateral healthy white matter. (1)H-MRSI indices were computed from these regions and compared between low- and high-grade gliomas. Using a similar approach, we applied a subgroup analysis to differentiate low- from high-grade oligodendrogliomas because they show different physiologic and genetic characteristics.

Results: Cho(glioma (G)/white matter (WM)), Glx(G/WM), and Lip+Lac(G)/Cr(WM) were significantly higher in the "hyperperfused" regions of high-grade gliomas compared with low-grade gliomas. Cho(G/WM) and Lip+Lac(G)/Cr(WM) were also significantly higher in the "hyperperfused" regions of high-grade oligodendrogliomas. However, metabolite ratios from the "hypoperfused" or "isoperfused" regions did not exhibit any significant differences between high-grade and low-grade gliomas.

Conclusion: The results suggest that (1)H-MRSI indices from the "hyperperfused" regions of gliomas, on the basis of PWI, may be helpful in distinguishing high-grade from low-grade gliomas including oligodendrogliomas.

Citing Articles

Amino acid metabolism in glioma: in vivo MR-spectroscopic detection of alanine as a potential biomarker of poor survival in glioma patients.

Alcicek S, Pilatus U, Manzhurtsev A, Weber K, Ronellenfitsch M, Steinbach J J Neurooncol. 2024; 170(2):451-461.

PMID: 39192067 PMC: 11538230. DOI: 10.1007/s11060-024-04803-2.

Challenges and opportunities for advanced neuroimaging of glioblastoma.

Henssen D, Meijer F, Verburg F, Smits M Br J Radiol. 2022; 96(1141):20211232.

PMID: 36062962 PMC: 10997013. DOI: 10.1259/bjr.20211232.

Emerging MR Imaging and Spectroscopic Methods to Study Brain Tumor Metabolism.

Kumar M, Nanga R, Verma G, Wilson N, Brisset J, Nath K Front Neurol. 2022; 13:789355.

PMID: 35370872 PMC: 8967433. DOI: 10.3389/fneur.2022.789355.

Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.

Chawla S, Bukhari S, Afridi O, Wang S, Yadav S, Akbari H NMR Biomed. 2022; 35(7):e4719.

PMID: 35233862 PMC: 9203929. DOI: 10.1002/nbm.4719.

3D pCASL-perfusion in preoperative assessment of brain gliomas in large cohort of patients.

Batalov A, Zakharova N, Pronin I, Belyaev A, Pogosbekyan E, Goryaynov S Sci Rep. 2022; 12(1):2121.

PMID: 35136119 PMC: 8826414. DOI: 10.1038/s41598-022-05992-4.

References

NISHIZUKA Y . Membrane phospholipid degradation and protein kinase C for cell signalling. Neurosci Res. 1992; 15(1-2):3-5. DOI: 10.1016/0168-0102(92)90013-3. View

Engelhard H, Stelea A, Cochran E . Oligodendroglioma: pathology and molecular biology. Surg Neurol. 2002; 58(2):111-7; discussion 117. DOI: 10.1016/s0090-3019(02)00751-6. View

Deimling A, Louis D, von Ammon K, Petersen I, Wiestler O, Seizinger B . Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res. 1992; 52(15):4277-9. View

Majos C, Alonso J, Aguilera C, Serrallonga M, Acebes J, Arus C . Adult primitive neuroectodermal tumor: proton MR spectroscopic findings with possible application for differential diagnosis. Radiology. 2002; 225(2):556-66. DOI: 10.1148/radiol.2252011592. View

Zagzag D, Zhong H, Scalzitti J, Laughner E, Simons J, Semenza G . Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000; 88(11):2606-18. View

Louis D, Holland E, Cairncross J . Glioma classification: a molecular reappraisal. Am J Pathol. 2001; 159(3):779-86. PMC: 1850454. DOI: 10.1016/S0002-9440(10)61750-6. View

Tate A, Majos C, Moreno A, Howe F, Griffiths J, Arus C . Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med. 2003; 49(1):29-36. DOI: 10.1002/mrm.10315. View

Rosenberg J, Lisle D, Burwick J, Ueki K, Deimling A, Mohrenweiser H . Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene. 1996; 13(11):2483-5. View

Cheng L, CHANG I, Louis D, Gonzalez R . Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res. 1998; 58(9):1825-32. View

10.

Hall W, Martin A, Liu H, Truwit C . Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. J Magn Reson Imaging. 2001; 13(1):12-5. DOI: 10.1002/1522-2586(200101)13:1<12::aid-jmri1002>3.0.co;2-q. View

11.

Stadlbauer A, Gruber S, Nimsky C, Fahlbusch R, Hammen T, Buslei R . Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology. 2006; 238(3):958-69. DOI: 10.1148/radiol.2382041896. View

12.

Lev M, Ozsunar Y, Henson J, Rasheed A, Barest G, Harsh 4th G . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004; 25(2):214-21. PMC: 7974605. View

13.

Alsop D, Detre J . Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab. 1996; 16(6):1236-49. DOI: 10.1097/00004647-199611000-00019. View

14.

Michaelis T, Merboldt K, Bruhn H, Hanicke W, Frahm J . Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology. 1993; 187(1):219-27. DOI: 10.1148/radiology.187.1.8451417. View

15.

Spampinato M, Smith J, Kwock L, Ewend M, Grimme J, Camacho D . Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol. 2006; 188(1):204-12. DOI: 10.2214/AJR.05.1177. View

16.

Hsu Y, Chang C, Wie K, Lim K, Hsu W, Jung S . Proton magnetic resonance spectroscopic imaging of cerebral gliomas: correlation of metabolite ratios with histopathologic grading. Chang Gung Med J. 2004; 27(6):399-407. View

17.

Runge V, Clanton J, Price A, Wehr C, Herzer W, Partain C . The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magn Reson Imaging. 1985; 3(1):43-55. DOI: 10.1016/0730-725x(85)90008-6. View

18.

Warmuth C, Gunther M, Zimmer C . Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology. 2003; 228(2):523-32. DOI: 10.1148/radiol.2282020409. View

19.

Hagberg G, Burlina A, Mader I, Roser W, Radue E, Seelig J . In vivo proton MR spectroscopy of human gliomas: definition of metabolic coordinates for multi-dimensional classification. Magn Reson Med. 1995; 34(2):242-52. DOI: 10.1002/mrm.1910340216. View

20.

Kaba S, Kyritsis A . Recognition and management of gliomas. Drugs. 1997; 53(2):235-44. DOI: 10.2165/00003495-199753020-00004. View